Aktuellt
SENASTE
Redeye returns with a follow-up note to Genovis’ Q1’22 report. We are encouraged to see that the company is reporting yet another solid quarter and that the growth remains high, particularly in the Enzyme business. We continue to see Genovis as an attractive investment for the long-term investor and reiterate our Base Case.
LÄS MER
